<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188824</url>
  </required_header>
  <id_info>
    <org_study_id>DMR99-IRB-137</org_study_id>
    <nct_id>NCT01188824</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study)</brief_title>
  <official_title>The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shin Kong Wu Ho-Su Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhua Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chi Mei Medical Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>E-DA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cathay General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>En Chu Kong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kuang Tien General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung Shan Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the Safety and Efficacy of Cilostazol in slowing&#xD;
      down the progression of peripheral arterial disease (PAD) in ischemic stroke patients with&#xD;
      PAD in Taiwan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One thousand patients will be randomized to take cilostazol (500 patients) or placebo (500&#xD;
      patients) in parallel groups. Patients will be screened and evaluated on Visits 1 to assess&#xD;
      their eligibility prior to randomization. The treatment period (Visit 1-6) will last 12&#xD;
      months and the patient will receive initial and follow-up evaluation (section 4.5) including&#xD;
      history and physical examinations, and baseline and end of treatment ABI and carotid IMT&#xD;
      assessments. Vascular events and death as well as adverse events including bleeding&#xD;
      complications will also be recorded at intervals as detailed in section 4.5.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint for this study is slowdown of PAD progression based on ABI.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Carotid intima-media thickness</measure>
    <time_frame>2 years</time_frame>
    <description>Carotid intima-media thickness.&#xD;
Vascular events, including recurrent stroke, myocardial infarction, unstable angina,other vascular events, and all death.&#xD;
Safety, including major bleeding events, hemorrhagic stroke, any death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">801</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pletaal® (Cilostazol) 100 mg, bid p.o.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo&#xD;
1 tablet, bid p.o.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>100 mg, bid p.o.</description>
    <arm_group_label>Cilostazol</arm_group_label>
    <other_name>Pletaal®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1 tablet, bid</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, age ≧50 years; for female patients, postmenopausal (defined&#xD;
             as at least 2 years without menses) has to be confirmed.&#xD;
&#xD;
          -  Ischemic stroke or transient ischemic attack patients who have been taking aspirin 100&#xD;
             mg, QD&#xD;
&#xD;
          -  Neurologically and clinically stable at inclusion&#xD;
&#xD;
          -  PAD (i.e. ankle-brachial index or ABI &lt;1.0)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to give informed consent&#xD;
&#xD;
          -  Patients with history of any type of hemorrhagic stroke (intracerebral&#xD;
             hemorrhage,subarachnoid hemorrhage, or others)&#xD;
&#xD;
          -  Modified Rankin Scale &gt;4&#xD;
&#xD;
          -  Patients with history of dementia requiring institutional care&#xD;
&#xD;
          -  Known brain tumor&#xD;
&#xD;
          -  Known anemia (defined as hemoglobin &lt;10.0 g/dL)&#xD;
&#xD;
          -  Known thrombocytopenia (defined as platelet count below 100,000/cm3)&#xD;
&#xD;
          -  AST or ALT &gt; 3 x Upper Normal Limit&#xD;
&#xD;
          -  Calculated creatinine clearance &lt; 30 ml/min according to the Copckroft formula)&#xD;
&#xD;
          -  Known hemostasis or coagulation disorder&#xD;
&#xD;
          -  Congestive heart failure, defined as a previous definitive diagnosis, or present&#xD;
             symptoms of at least Category II of the NYHA classification system for CHF&#xD;
&#xD;
          -  Revascularization of the lower limb arteries including bypass surgery, endovascular&#xD;
             procedures&#xD;
&#xD;
          -  Symptomatic PAD requiring treatment with cilostazol&#xD;
&#xD;
          -  Known stenosis of the upper limb arteries that may affect the documentation of ABI&#xD;
&#xD;
          -  Patients with known hypersensitivity to cilostazol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chung Y. Hsu, MD. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>August 23, 2010</study_first_submitted>
  <study_first_submitted_qc>August 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2010</study_first_posted>
  <last_update_submitted>September 30, 2013</last_update_submitted>
  <last_update_submitted_qc>September 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

